Literature DB >> 18587425

Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro.

K L Aughton1, K Hamilton-Smith, J Gupta, J S Morton, C P Wayman, V M Jackson.   

Abstract

BACKGROUND AND
PURPOSE: Hypothalamic neuropeptides centrally modulate sexual arousal. However, the role of neuropeptides in peripheral arousal has been ignored. Vascular and non-vascular smooth muscle relaxation in the vagina is important for female sexual arousal. To date, in vitro studies have focused on vaginal strips with no studies on vaginal arteries. The aim of this study was to compare the effects of sexual hypothalamic neuropeptides on rabbit vaginal wall strips and arteries. EXPERIMENTAL APPROACH: Tissue bath and wire myography techniques were used to measure isometric tension from strips and arteries, respectively. KEY
RESULTS: Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) relaxed both preparations, effects that were only antagonized by the VIP/PACAP antagonist VIP6-28 (10 nM) and the PAC(1) antagonist PACAP 6-38 (1 microM). The melanocortin agonist alpha-melanocortin-stimulating hormone (1 microM), but not bremelanotide (1 microM), also relaxed both preparations. Oxytocin and vasopressin contracted vaginal preparations, which could be antagonized by the V(1A) antagonist SR 49059. Neuropeptide Y (NPY) and the NPY Y(1) agonist Leu(31), Pro(34) NPY only contracted arteries, which was antagonized by the NPY Y(1) receptor antagonist BIBP 3226. Melanin-concentrating hormone (MCH; 1 microM) contracted arteries. CONCLUSION AND IMPLICATIONS: Hypothalamic neuropeptides can exert contractile and relaxant effects on vaginal strips and arteries. NPY Y(1), V(1A), MCH(1) antagonists as well as VIP/PAC(1) agonists may have therapeutic potential in both central and peripheral female sexual arousal. Differences in effect of neuropeptides between preparations raise the question of which preparation is important for female sexual arousal.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587425      PMCID: PMC2538698          DOI: 10.1038/bjp.2008.253

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Central oxytocin and female sexual behavior.

Authors:  J D Caldwell
Journal:  Ann N Y Acad Sci       Date:  1992-06-12       Impact factor: 5.691

Review 2.  Analysis of competitive agonist-antagonist interactions by nonlinear regression.

Authors:  M J Lew; J A Angus
Journal:  Trends Pharmacol Sci       Date:  1995-10       Impact factor: 14.819

3.  Differential signal transduction by five splice variants of the PACAP receptor.

Authors:  D Spengler; C Waeber; C Pantaloni; F Holsboer; J Bockaert; P H Seeburg; L Journot
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

4.  Innervation of vasculature and microvasculature of the human vagina by NOS and neuropeptide-containing nerves.

Authors:  C H Hoyle; R W Stones; T Robson; K Whitley; G Burnstock
Journal:  J Anat       Date:  1996-06       Impact factor: 2.610

5.  Oxytocin enhances, and oxytocin antagonism decreases, sexual receptivity in intact female rats.

Authors:  A Benelli; R Poggioli; P Luppi; L Ruini; A Bertolini; R Arletti
Journal:  Neuropeptides       Date:  1994-10       Impact factor: 3.286

6.  Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Authors:  C Serradeil-Le Gal; J Wagnon; C Garcia; C Lacour; P Guiraudou; B Christophe; G Villanova; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Helospectin and pituitary adenylate cyclase activating polypeptide in the human vagina.

Authors:  A H Graf; A Schiechl; G W Hacker; C Hauser-Kronberger; H Steiner; A Arimura; F Sundler; A Staudach; O Dietze
Journal:  Regul Pept       Date:  1995-02-14

8.  Infusion of an oxytocin antagonist into the medial preoptic area prior to progesterone inhibits sexual receptivity and increases rejection in female rats.

Authors:  J D Caldwell; J M Johns; B M Faggin; M A Senger; C A Pedersen
Journal:  Horm Behav       Date:  1994-09       Impact factor: 3.587

Review 9.  PDE5 inhibitors beyond erectile dysfunction.

Authors:  P Sandner; J Hütter; H Tinel; K Ziegelbauer; E Bischoff
Journal:  Int J Impot Res       Date:  2007-07-12       Impact factor: 2.896

10.  Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.

Authors:  H N Doods; W Wienen; M Entzeroth; K Rudolf; W Eberlein; W Engel; H A Wieland
Journal:  J Pharmacol Exp Ther       Date:  1995-10       Impact factor: 4.030

View more
  4 in total

1.  UK-414,495, a selective inhibitor of neutral endopeptidase, potentiates pelvic nerve-stimulated increases in female genital blood flow in the anaesthetized rabbit.

Authors:  C P Wayman; D Baxter; L Turner; P H Van Der Graaf; A M Naylor
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

Review 2.  Female sexual dysfunction: therapeutic options and experimental challenges.

Authors:  Kyan J Allahdadi; Rita C A Tostes; R Clinton Webb
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-10

3.  A neuropeptide speeds circadian entrainment by reducing intercellular synchrony.

Authors:  Sungwon An; Rich Harang; Kirsten Meeker; Daniel Granados-Fuentes; Connie A Tsai; Cristina Mazuski; Jihee Kim; Francis J Doyle; Linda R Petzold; Erik D Herzog
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

4.  Overexpressing miR-122-5p Inhibits the Relaxation of Vaginal Smooth Muscle in Female Sexual Arousal Disorder by Targeting Vasoactive Intestinal Peptide Receptor 1.

Authors:  Shengnan Cong; Tao Gui; Qinchuan Shi; Jingjing Zhang; Jingyi Feng; Lianjun Pan; Jiehua Ma; Aixia Zhang
Journal:  Sex Med       Date:  2021-07-08       Impact factor: 2.491

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.